Ozempic and Wegovy may be beneficial in fighting alcohol addiction: Study
The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...
来自MSN3 小时
Ozempic Could Help Curb Alcoholism
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for ...
Weight loss drugs Ozempic and Wegovy may also curb alcohol addiction, study says
A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...
Ozempic, Wegovy Linked To Lower Hospitalizations In Alcohol Addicts, Research Shows
GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...
腾讯网7 天
诺和诺德重磅疗法3期试验积极，明年将再递交监管申请
2024年9月，诺和诺德成功完成了STRIDE临床3b期试验。这是一项为期52周的试验，比较了1.0 ...
减肥药致10人死亡100人住院！司美格鲁肽仿制药存安全问题
快科技11月11日消息，据报道，诺和诺德公司的首席财务官Karsten Munk Knudsen表示，该公司畅销的减肥药复方仿制药已导致100人住院，并有10人不幸丧生。
Ozempic and Wegovy may help curb alcohol addiction, study suggests
The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...
Why could Ozempic play a role in reducing the risk of Alzheimer's disease?
Researchers at Case Western Reserve school of Medicine looked at nearly one million patients in the U.S. with Type 2 diabetes ...
Yahoo6 天
Ozempic for Perimenopause? Ob-Gyn Explains How Semaglutide May Help
Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...
金融界财经 on MSN7 天
诺和诺德(NVO.US)警告：复方仿制减肥药已致10人死亡
智通财经APP获悉，诺和诺德(NVO.US)首席财务官Karsten Munk Knudsen周三表示，该公司了解到，有100人因服用其畅销减肥药和糖尿病药的复方仿制药而住院，10人死亡。
来自MSN2 天
Does Ozempic Cause Hair Loss? Here's What Doctors Say About the Semaglutide Side Effect
A s doctors and researchers learn more about Ozempic's health benefits, many are impressed. Besides lowering blood sugar in ...
jandan.net6 天
比Ozempic更强：新一代减肥药减重效果提升25%
不过，Novo Nordisk开发副总裁Martin Holst Lange向分析师表示，他“有信心”更大规模的试验会证明CagriSema能帮助用户减重多达25%。Lange指出，公司基于先前试验的数据得出了这一预测。 Novo Nordisk表示，根据此前的试验，这款新药的安全性和耐受性预计与当前市面上的GLP-1药物相似。